Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed TherapiesMaximilian Merz, Uwe Platzbecker, Jule Ussmann et al.|Blood|2022Cited by 1
P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myelomaLuise Fischer, Ulrike Köhl, Nora Grieb et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0
P-105 PET/CT Has Prognostic Significance for CAR T Cell Therapy in Relapsed/Refractory Multiple MyelomaPatrick Born, Maximilan Merz, David Fandrei et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0